Michael Kaseta Sells 3,000 Shares of Liquidia (NASDAQ:LQDA) Stock

Key Points

• Liquidia CFO Michael Kaseta sold 3,000 shares on April 14 at $40 under a pre-arranged Rule 10b5-1 plan; across multiple April transactions he disposed of roughly 318,958 shares for about $12.8M and now holds 405,775 shares valued at ~$16.23M.
• Shares recently traded at $41.40 with a market cap of $3.65B and a 1‑year range of $11.85–$46.67; the company beat quarterly EPS and revenue estimates but still reports negative net margin and return on equity.
• Wall Street sentiment is broadly positive with an average rating of “Moderate Buy” and a consensus target of $43.44, including several firms issuing Buy/Strong‑Buy notes and higher price targets.

Liquidia Corporation (NASDAQ:LQDA - Get Free Report) CFO Michael Kaseta sold 3,000 shares of the firm's stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $40.00, for a total transaction of $120,000.00. Following the sale, the chief financial officer owned 405,775 shares of the company's stock, valued at $16,231,000. This represents a 0.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Kaseta also recently made the following trade(s):

• On Wednesday, April 15th, Michael Kaseta sold 139,390 shares of Liquidia stock. The shares were sold at an average price of $40.14, for a total transaction of $5,595,114.60.
• On Monday, April 13th, Michael Kaseta sold 18,958 shares of Liquidia stock. The stock was sold at an average price of $38.37, for a total transaction of $727,418.46.
• On Friday, April 10th, Michael Kaseta sold 23,821 shares of Liquidia stock. The stock was sold at an average price of $40.14, for a total transaction of $956,174.94.
• On Thursday, April 9th, Michael Kaseta sold 133,789 shares of Liquidia stock. The stock was sold at an average price of $40.24, for a total transaction of $5,383,669.36.

Liquidia Stock Performance

Shares of Liquidia stock traded up $1.28 on Thursday, reaching $41.40. 1,184,168 shares of the stock were exchanged, compared to its average volume of 983,955. The firm has a market capitalization of $3.65 billion, a PE ratio of -49.88 and a beta of 0.45. Liquidia Corporation has a 1-year low of $11.85 and a 1-year high of $46.67. The business has a fifty day moving average price of $36.63 and a two-hundred day moving average price of $33.14. The company has a current ratio of 2.01, a quick ratio of 1.84 and a debt-to-equity ratio of 2.97.

Liquidia (NASDAQ:LQDA - Get Free Report) last released its quarterly earnings data on Thursday, March 5th. The company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of $0.08 by $0.07. The firm had revenue of $92.02 million for the quarter, compared to the consensus estimate of $87.49 million. Liquidia had a negative net margin of 43.53% and a negative return on equity of 209.33%. The business's quarterly revenue was up 3072.4% on a year-over-year basis. As a group, research analysts anticipate that Liquidia Corporation will post -1.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Needham & Company LLC increased their price target on shares of Liquidia from $52.00 to $54.00 and gave the stock a "buy" rating in a research note on Thursday, March 5th. Raymond James Financial reiterated a "strong-buy" rating on shares of Liquidia in a research note on Thursday, March 5th. Wall Street Zen upgraded shares of Liquidia from a "hold" rating to a "buy" rating in a research report on Saturday, March 7th. Lifesci Capital raised shares of Liquidia to a "strong-buy" rating in a research note on Thursday, March 5th. Finally, Oppenheimer raised their target price on shares of Liquidia from $16.00 to $19.00 and gave the company an "underperform" rating in a research note on Thursday, March 12th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Liquidia has an average rating of "Moderate Buy" and a consensus target price of $43.44.

Institutional Investors Weigh In On Liquidia

A number of institutional investors have recently bought and sold shares of LQDA. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Liquidia in the 4th quarter valued at $25,000. NewEdge Advisors LLC bought a new stake in Liquidia during the 2nd quarter worth about $25,000. Skandinaviska Enskilda Banken AB publ bought a new stake in Liquidia during the 3rd quarter worth about $30,000. FNY Investment Advisers LLC bought a new stake in Liquidia during the 3rd quarter worth about $34,000. Finally, Covestor Ltd raised its holdings in Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company's stock worth $42,000 after purchasing an additional 359 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company's stock.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company's lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.